Therapeutic potential of ERK5 targeting in triple negative breast cancer

Triple negative breast cancers (TNBCs) account for 15% of all breast cancers, and represent one of the most aggressive forms of the disease, exhibiting short relapse-free survival. In contrast to other breast cancer subtypes, the absence of knowledge about the etiopathogenic alterations that cause T...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Ortiz-Ruiz, María Jesús, Álvarez-Fernández, Stela, Parrott, Tracy, Zaknoen, Sara, Burrows, Francis J., Ocaña, Alberto, Pandiella, Atanasio, Esparís-Ogando, Azucena
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2014
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4294347/
https://ncbi.nlm.nih.gov/pubmed/25350956
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky